Missouri Trust & Investment Co Has $1.45 Million Holdings in Pfizer Inc. (NYSE:PFE)

Missouri Trust & Investment Co raised its position in Pfizer Inc. (NYSE:PFE) by 8.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,956 shares of the biopharmaceutical company’s stock after buying an additional 3,885 shares during the period. Missouri Trust & Investment Co’s holdings in Pfizer were worth $1,446,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Olistico Wealth LLC bought a new position in Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at $29,000. Quarry LP purchased a new stake in shares of Pfizer during the 2nd quarter valued at $31,000. Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the 2nd quarter valued at $34,000. Finally, ESL Trust Services LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Performance

PFE stock traded up $0.16 during midday trading on Tuesday, reaching $26.40. 7,890,148 shares of the company’s stock traded hands, compared to its average volume of 37,524,527. The stock has a market cap of $149.61 billion, a P/E ratio of 35.46, a PEG ratio of 0.85 and a beta of 0.67. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The stock’s 50-day moving average is $28.84 and its 200 day moving average is $28.67. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same period in the prior year, the business posted ($0.17) earnings per share. The company’s revenue was up 31.2% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.36%. Pfizer’s dividend payout ratio is presently 227.03%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price on the stock. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.